[go: up one dir, main page]

NO20063794L - Tetrahydroisoquinolin- og tetrahydrobenzazepin-derivater som IGF-1R-inhibitorer - Google Patents

Tetrahydroisoquinolin- og tetrahydrobenzazepin-derivater som IGF-1R-inhibitorer

Info

Publication number
NO20063794L
NO20063794L NO20063794A NO20063794A NO20063794L NO 20063794 L NO20063794 L NO 20063794L NO 20063794 A NO20063794 A NO 20063794A NO 20063794 A NO20063794 A NO 20063794A NO 20063794 L NO20063794 L NO 20063794L
Authority
NO
Norway
Prior art keywords
igf
tetrahydroisoquinoline
inhibitors
tetrahydrobenzazepine derivatives
tetrahydrobenzazepine
Prior art date
Application number
NO20063794A
Other languages
English (en)
Inventor
Jan Gunzinger
Kurt Leander
Original Assignee
Analytecon Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Analytecon Sa filed Critical Analytecon Sa
Publication of NO20063794L publication Critical patent/NO20063794L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Forbindelser i samsvar med formel (I): hvor R2, R5, R6 er som angitt i beskrivelsen, og U, V og W kan være henholdsvis CR2', CR4` og CR6` (hvor definisjonene av R2', RV og R6' igjen er angitt i beskrivelsen), eller kan være N, når syntetisk fremstilt. Det fremlegges at de nedregulerer eller inhiberer ekspresjonen eller funksjonen av IGF-1 reseptoren.
NO20063794A 2004-03-12 2006-08-24 Tetrahydroisoquinolin- og tetrahydrobenzazepin-derivater som IGF-1R-inhibitorer NO20063794L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CH2004/000147 WO2005087743A1 (en) 2004-03-12 2004-03-12 Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors

Publications (1)

Publication Number Publication Date
NO20063794L true NO20063794L (no) 2006-12-12

Family

ID=34957074

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063794A NO20063794L (no) 2004-03-12 2006-08-24 Tetrahydroisoquinolin- og tetrahydrobenzazepin-derivater som IGF-1R-inhibitorer

Country Status (21)

Country Link
US (1) US7875631B2 (no)
EP (1) EP1732898B1 (no)
JP (1) JP2007528877A (no)
CN (1) CN100590118C (no)
AR (1) AR049323A1 (no)
AT (1) ATE384700T1 (no)
AU (1) AU2004317166B2 (no)
BR (1) BRPI0418462A (no)
CA (1) CA2555745C (no)
DE (1) DE602004011578T2 (no)
DK (1) DK1732898T3 (no)
EA (1) EA200601687A1 (no)
ES (1) ES2299825T3 (no)
IL (1) IL177307A (no)
NO (1) NO20063794L (no)
PL (1) PL1732898T3 (no)
PT (1) PT1732898E (no)
SI (1) SI1732898T1 (no)
TW (1) TW200530213A (no)
WO (1) WO2005087743A1 (no)
ZA (1) ZA200607198B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007029107A1 (en) * 2005-09-09 2007-03-15 Analytecon Sa Isoquinolines derivatives as igf-1r inhibitors
JP2009507819A (ja) * 2005-09-09 2009-02-26 アナリットコン エス アー Ｉｇｆ−１ｒ阻害剤としてのイソキノリン
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
WO2011112666A1 (en) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
BR112013000254A2 (pt) 2010-07-05 2016-05-24 Actelion Pharmaceuticals Ltd derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
JP6268097B2 (ja) 2011-11-11 2018-01-24 デューク・ユニヴァーシティ 固形腫瘍治療のための併用薬物療法
WO2013093842A1 (en) 2011-12-21 2013-06-27 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
CN104428305A (zh) 2012-07-05 2015-03-18 埃科特莱茵药品有限公司 1-苯基-取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CN104672136B (zh) * 2013-11-30 2017-01-25 沈阳药科大学 1‑取代菲基‑n‑烷基(酰基)‑6,7‑二甲氧基‑1,2,3,4‑四氢异喹啉衍生物及其制备方法和用途
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
CN112500345B (zh) * 2020-12-18 2022-06-21 西安石油大学 α-氰基季碳取代四氢异喹啉化合物的合成方法
WO2024067463A1 (zh) * 2022-09-27 2024-04-04 苏州阿尔脉生物科技有限公司 苯并[7]环烯类衍生物、包含其的药物组合物及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4349472A (en) * 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
CA1330560C (en) * 1986-05-21 1994-07-05 Maurits E. A. Vandewalle Di- and tetrahydroisoquinoline derivatives
WO1990002119A1 (fr) * 1988-08-18 1990-03-08 Banyu Pharmaceutical Co., Ltd. Derives de 1,2,3,4-tetrahydro-isoquinoline
WO2000035455A1 (en) * 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
EP1341765A1 (en) * 2000-12-07 2003-09-10 AstraZeneca AB Therapeutic compounds
SE0102168D0 (sv) 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
GB0212303D0 (en) 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor

Also Published As

Publication number Publication date
BRPI0418462A (pt) 2007-06-05
AR049323A1 (es) 2006-07-19
ES2299825T3 (es) 2008-06-01
DK1732898T3 (da) 2008-05-13
WO2005087743A1 (en) 2005-09-22
US7875631B2 (en) 2011-01-25
CA2555745C (en) 2011-05-31
PL1732898T3 (pl) 2008-06-30
JP2007528877A (ja) 2007-10-18
IL177307A (en) 2011-09-27
PT1732898E (pt) 2008-04-07
CA2555745A1 (en) 2005-09-22
AU2004317166B2 (en) 2010-11-11
US20070129399A1 (en) 2007-06-07
IL177307A0 (en) 2006-12-10
EP1732898A1 (en) 2006-12-20
ATE384700T1 (de) 2008-02-15
DE602004011578D1 (de) 2008-03-13
SI1732898T1 (sl) 2008-06-30
TW200530213A (en) 2005-09-16
CN100590118C (zh) 2010-02-17
CN1922147A (zh) 2007-02-28
EA200601687A1 (ru) 2007-04-27
EP1732898B1 (en) 2008-01-23
DE602004011578T2 (de) 2009-02-19
ZA200607198B (en) 2008-04-30
AU2004317166A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
NO20063794L (no) Tetrahydroisoquinolin- og tetrahydrobenzazepin-derivater som IGF-1R-inhibitorer
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
EP2862859A3 (en) Compounds, compositions and methods
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
NO20066055L (no) Pyridinderivater
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
HK1079788A1 (zh) 适用於治疗2型糖尿病的作为葡萄糖激酶活化剂的取代的(噻唑-2-基)-酰胺或磺胺
WO2004096798A3 (fr) Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique
WO2003076398A3 (en) Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
WO2004064730A3 (en) Compounds, compositions and methods
NO20051103L (no) Indol-3-karboksamider som Glukokinase-(GK)-Aktivatorer
MX2009003821A (es) Compuestos de n-aril pirazol para usarse contra la diabetes.
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
WO2003095398A3 (en) Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same
WO2007007042A8 (en) Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
WO2006061417A3 (en) Macrocyclic quinazole derivatives and their use as mtki
BRPI0407841A (pt) inibidores heterocìclicos de quinase
WO2004043362A3 (en) Acyl guanidine compounds and use thereof
CO5690551A2 (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
WO2006008545A3 (en) Thiazole and isothiazole derivatives as protein kinase inhibitors
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application